Project: Research project

Project Details


DESCRIPTION: (Adapted from the investigator's abstract) Breast cancer is the
most common cancer and the second leading cause of cancer deaths among women.
The majority of patients present with operable disease. In fact, most patients
with node-negative disease will be cured by surgical resection of their tumor
alone. However, due to proven efficacy, most patients with invasive breast
cancer will undergo a complete axillary dissection for lymph node evaluation,
and are considered candidates for adjuvant (systemic) therapy. This subjects
the majority of patients with node-negative disease to the expense and side
effects of axillary dissection and systemic chemotherapy. Primary treatment
failure is secondary to undetectable spread of tumor, and this occult tumor is
the target of adjuvant therapy. He has developed extremely sensitive methods
for the detection of occult metastases in bone marrow (BM) and regional lymph
nodes in patients with breast cancer. Studies from their laboratory and others
strongly suggest that the presence of occult regional and systemic metastases
are associated with increased recurrence and decreased survival. Furthermore,
he has shown that the identification and analysis of the sentinel lymph node
(SLN, the first lymph node draining the tumor bed) may reduce the need for
complete axillary dissection, particularly in patients with node-negative
disease. Their central hypothesis is that the presence of occult metastases to
BM and SLN in patients with early stage breast cancer identifies patients at
increased risk of recurrence and death, and identifies the specific target of
adjuvant chemotherapy. The specific aims are: (1) To identify and quantitate
occult metastases in BM and SLN of patients with breast cancer. This study will
be organized by the NIH/NCI funded American College of Surgeons Oncology Group
(ACOS-OG), (protocol Z0010). (2) Because they understand the difficulties of
current methods to detect occult metastases, he has developed and will evaluate
novel imaging and molecular methods for the detection of occult metastases. (3)
To evaluate, through the ACOS-OG data management and follow up capabilities,
the clinical significant of occult metastases to BM and SLN. This study will
provide the essential correlative research component for the ACOS-OG
multi-center clinical trial Z0010, and should provide definitive evidence
regarding the use of occult metastasis detection in patients with breast
cancer. The detection of occult metastases in BM and SLN, in place of more
radical axillary dissection, could allow for more specific yet less invasive
assessment of patient risk, and redefine the surgical and systemic treatment
options for patients with breast cancer.
Effective start/end date6/20/005/31/06


  • National Cancer Institute: $491,893.00
  • National Cancer Institute: $455,226.00
  • National Cancer Institute: $465,150.00
  • National Cancer Institute: $478,323.00
  • National Cancer Institute: $455,712.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.